Hyperfine has enrolled the first patients in its NEURO PMR study, evaluating the clinical utility of its Swoop portable MRI system. The Swoop device is the world’s first FDA-cleared, ultra-low-field, brain MRI designed for use in outpatient settings.
The multi-center study aims to compare Swoop’s diagnostic performance with conventional high-field MRIs, focusing on clinical outcomes, pathology findings, and patient experience. Targeting 100 participants, the study is expected to conclude by year-end.
Hyperfine is leveraging AI to enhance image quality and streamline neurology diagnostics. The company sees the study as a key step in expanding its market reach into outpatient and rural clinics.
Dr. Laszlo Mechtler of DENT Neurologic Institute emphasized the goal of making advanced imaging more accessible and efficient. Dr. Gincy Samuel of Texas Neurology added, “This technology offers vital imaging access to underserved communities and aligns with the shift toward integrated outpatient care.”
Follow MEDWIRE.AI for AI-powered imaging insights.
